Listen Now

The continent is suffering a third wave of covid-19 after the European Commission’s vaccine roll out stalled. French President Emmanuelle Macron has said Europe “lacked ambition” in its vaccine efforts. How can European countries catch up? Alok Jha and Natasha Loder are joined by Sophie Pedder, The Economist’s Paris bureau chief, Stanley Pignal, European business and finance correspondent, and Sondre Solstad, senior data journalist. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

All adults in America are now eligible for a covid-19 vaccine. Around 30% of those polled in the country, however, are hesitant to take the jab. A shortage of vaccines will soon become a shortage of arms. What is the best way to persuade reluctant citizens to get inoculated? We speak to Heidi Larson, anthropologist at the London School of Hygiene and Tropical Medicine and founding director of the Vaccine Confidence Project, about the similarities between vaccine hesitancy today and the 19th century. Crystal Son, director of healthcare analytics at Civis Analytics, on why vaccine safety messaging is ineffective. Alok Jha and Natasha Loder are joined by Edward Carr, The Economist’s deputy editor, and Tamara Gilkes Borr, US policy correspondent. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

More than a billion doses of covid-19 vaccine have been made. Now comes the hard part: ensuring every country in the world has access to them. Can distribution be made more equitable?  Alok Jha and Natasha Loder are joined by Edward Carr, The Economist’s deputy editor, and Sondre Solstad, senior data journalist. With Seth Berkley of GAVI, the Vaccine Alliance, and John Nkengasong, director of the Africa Centres for Disease Control and Prevention. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts   See acast.com/privacy for privacy and opt-out information.

The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?  Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.  Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts    See acast.com/privacy for privacy and opt-out information.

The EU was slow to roll out covid-19 vaccines, then destroyed confidence in the Astrazeneca vaccine and is now embroiled in a row over supplies. Will America avoid Europe's pitfalls? Dr Anthony Fauci, chief medical adviser to President Biden, explains vaccination progress in America, the plateau of new infections and his plan to combat new variants. Also, how does America's federal system affect the vaccination programme?Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Edward Carr, The Economist's deputy editor and our New York correspondent Rosemarie Ward join them.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

The world has stumbled through the pandemic by nationalising risk. In heavily infected countries citizens have been ordered to stay home for weeks at a time. As covid-19 vaccination programmes spread, governments must gradually restore choice to the individual. How?We speak to Ozlem Tureci and Ugur Sahin—the couple who co-founded BioNTech which created the first covid-19 vaccine to get regulatory approval. Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. The Economist's deputy editor Edward Carr, Europe correspondent Vendeline Von Bredow and Dan Rosenheck from our data team join them.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

Large scale covid-19 vaccine trials have taken place at exceptional speed with unprecedented scrutiny. How do they work? And why are the results so politically charged? We speak to Andrew Catchpole, lead scientist on the first trial to infect volunteers with the virus intentionally. Jason Palmer, presenter of The Intelligence, assists in a trial. Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Slavea Chankova, The Economist's health-care correspondent, and James Fransham, from our data team, join them.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

It is one thing to design and test covid-19 vaccines. It is another to make them at sufficient scale to generate the billions of doses needed to vaccinate the world’s population. How are the vaccines produced, why is production so variable and will it meet demand this year?We speak to Adar Poonawalla, CEO of the Serum Institute of India, the world's biggest supplier of vaccines. The Economist’s technology correspondent Hal Hodson explains why some vaccines take longer to produce than others. James Fransham from our data team discusses when supply will meet demand.Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, The Economist's briefing editor, joins them.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science newsletter at economist.com/simplyscience and data newsletter at economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

Three vaccines have been approved by stringent regulators. Ten are being used in one or more countries. How do they work and are they effective enough against new variants of the coronavirus?Sarah Gilbert, inventor of the Oxford/Astrazeneca vaccine, tells us adapting to new variants should be easy. The Economist’s Beijing bureau chief David Rennie reports from China, which faces a huge test of its homegrown vaccine technology as it tries to re-open. James Fransham from our data team on how far the variants have spread.Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Slavea Chankova, The Economist's health-care correspondent, joins them.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod and sign up for our new weekly science newsletter at economist.com/simplyscience  See acast.com/privacy for privacy and opt-out information.

The race between infections and injections is in its most crucial phase. What life is like on the other side of the pandemic depends on three things: how well vaccines work, whether there are enough and how many people take them.Michael Osterholm, an epidemiologist who has advised President Biden, tells us the world stands at an inflection point. After getting his jab in Jerusalem, our correspondent there says the vision of the future Israel offers other countries is not as rosy as it first seemed. James Fransham from The Economist data team unpicks the vaccination numbers so far. Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Edward Carr, The Economist's deputy editor, joins them.For full access to The Economist’s print, digital and audio editions subscribe here: economist.com/thejabpodSubscribe to our new weekly science newsletter at economist.com/simplyscience and data newsletter at www.economist.com/offthecharts  See acast.com/privacy for privacy and opt-out information.

In this new weekly podcast series, The Economist unlocks the science, data and politics behind the most ambitious inoculation programme the world has ever seen.Alok Jha, The Economist’s science correspondent, hosts with Natasha Loder, our health-policy editor. Each week our reporters and data journalists join them in conversation, along with scientists around the world. They inject the perfect dose of insight and analysis into the global effort to escape the pandemic.   See acast.com/privacy for privacy and opt-out information.